**Core tip:** This systematic review demonstrates that the over-the-scope clip (OTSC) system is a safe and effective endoscopic therapy to manage gastrointestinal hemorrhage, perforations, anastomotic leaks, defects created by endoscopic resections and for stent fixation. Clinical success in fistula management appears limited. Further studies, including randomized controlled trials comparing OTSC with conventional and/or surgical therapies, are needed to determine which indication(s) are the most effective for its use.

INTRODUCTION
============

Acute (primary or refractory) gastrointestinal (GI) hemorrhage, perforation, GI fistulae, and anastomotic leaks are frequent occurrences in clinical GI practice that have been conventionally managed with surgery; however, the over-the-scope-clip (OTSC) system (Ovesco Endoscopy AG, Tübingen, Germany) has increasingly become an effective endoscopic treatment option in many cases as a primary and salvage treatment option, thereby decreasing the need for surgical intervention.

The OTSC system is a novel mechanical clipping device that allows for the endoscopic closure of large GI defects. It consists of an applicator cap, mounted clip, a hand wheel, thread, and thread retriever\[[@B1]\]. The clip is made of a super-elastic alloy (Nitinol), which is a biocompatible and magnetic resonance imaging conditional material (can be retained as a long-term implant)\[[@B1]\]. The applicator cap is available in a variety of sizes to accommodate endoscopes of different diameters (Table [1](#T1){ref-type="table"}). The OTSC clips are offered in three different shapes (a, t, and gc) amenable to each indication: (1) Type "a" clips are blunted to provide compression of tissues and primarily used for hemostasis; (2) Type "t" clips have small spikes and blunted edges allowing for both compression and anchoring into tissues, and can be used for relatively thin walled portions of the GI tract such as the small intestine or colon; and (3) Type "gc" clips have elongated teeth (with spikes), which are primarily indicated for closure of gastric wall defects (Figure [1](#F1){ref-type="fig"})\[[@B1]\]. Auxiliary accessories have recently become commercially available, including a clip designed for stent-fixation (Stentfix OTSC system; Ovesco Endoscopy AG, Tübingen, Germany), a smaller diameter applicator and clip for smaller lumens (mini OTSC; Ovesco Endoscopy AG, Tübingen, Germany), full thickness resection device (FTRD, Ovesco Endoscopy AG, Tübingen, Germany), and two forceps-like devices (OTSC Anchor, OTSC Twin Grasper; Ovesco Endoscopy AG, Tübingen, Germany). The Twin Grasper (TG) facilitates the approximation of gaping edges of a lesion prior to deployment of the OTSC clip (Figure [2](#F2){ref-type="fig"}), whereas the Anchor is able precisely align the target tissue and applicator cap, thus allowing for better approximation of tissue (especially when indurated)\[[@B1]\].

###### 

Over-the-scope clip types available for endoscope diameter and applicator clip depth^2^

  **OTSC cap options**                                                                                                                              
  ------------------------------------ ------------------------- --------------------------------------- ------------------------------------------ ------------
  Scope outer diameter compatibility   8.5-9.8 mm                8.5-11 mm                               10.5-12 mm                                 11.5-14 mm
  Diagnostic gastroscopes              Diagnostic gastroscopes   1T/2T gastroscopes, peds colonoscopes   Adult colonoscopes                         
  Maximum outer diameter of cap        14.65 mm                  16.5 mm                                 17.5 mm                                    21 mm
  Thread length                        165 cm                    165 cm                                  165 cm or 220 cm                           220 cm
  Depth of applicator cap                                                                                                                           
  3 mm                                 a, t                      a, t                                    a, t                                       a, t
  6 mm                                 N/A                       a, t                                    a, t, gc[1](#T1FN1){ref-type="table-fn"}   a, t

Type "a" clips: Blunt teeth; Type "t": Teeth with small spikes; Type "gc": Teeth with elongated spikes (only available in size 12 cap); ^2^Adapted from Over the scope clip System Brochure (Ovesco Endoscopy AG, Tübingen, Germany)\[[@B1]\]. N/A: Not applicable.

![Over-the-scope clip types. A: Type "atraumatic"; B: Type "traumatic"; C: Type "gastric closure". Use of images with permission from Ovesco Endoscopy AG (Tübingen, Germany).](WJG-26-3495-g001){#F1}

![Over the scope clip accessories. A: Over-the-scope clip Anchor; B: Over-the-scope clip Twin Grasper.](WJG-26-3495-g002){#F2}

The OTSC is delivered by means of an applicator cap mounted to the end of the endoscope using a thread retriever. If necessary, the TG or Anchor forceps may be used to allow for better approximation of the lesion. Turning the hand wheel attached to the working channel of the endoscope allows for the thread connected to the applicator cap to tighten, thus deploying the clip to the targeted defect\[[@B1]\]. An additional clip may be used if a single clip does not sufficiently achieve adequate closure.

Kirschniak et al\[[@B2]\] first reported the clinical application of OTSC in 2007. The authors described seven refractory bleeding events, two iatrogenic perforations and two defects following endoscopic resection that were successfully managed with OTSC. A significant advantage of the OTSC system is the ability to achieve closure of luminal defects, or complex bleeding lesions with the deployment of a single clip, thus making its deployment more efficient than prior endoscopic strategies which utilized multiple through the scope (TTS) clips\[[@B3],[@B4]\]. Prior to the availability of OTSC, complex luminal defects encountered during endoscopic procedures were often unable to be closed with conventional TTS clips due to lack of their ability to adequately approximate the defect margins, thus requiring surgical intervention in many instances. Furthermore, in the context of GI hemorrhage, the literature supports the use of OTSC when conventional endoscopic therapies fail\[[@B5],[@B6]\].

Advancements in therapeutic interventions across endoscopic practice currently facilitate larger and deeper resections of GI lesions, with a concurrent increase in iatrogenic injury\[[@B7]-[@B9]\]. OTSC has utility as a "real-time" intervention, allowing the endoscopist to effectively manage adverse events (AEs) quickly (such as bleeding and perforation) during the index procedure.

Since its inception, OTSC has become integrated into endoscopic practice internationally, with varying degrees of clinical success\[[@B10]-[@B12]\]. Though the OTSC system has been available for over ten years, it continues to benefit from iteration as further product development continues to take place. Data describing its use in the treatment of GI hemorrhage, perforation, anastomotic leaks, fistulae, defect closure after endoscopic resection and stent fixation is limited to primarily retrospective cohort studies and case series. Compiling and studying these published data in an organized manner would provide a more comprehensive understanding of the efficacy and safety profile of OTSC. This systematic review aims to determine the clinical success and AE rates of OTSC across various GI indications for use.

MATERIALS AND METHODS
=====================

Literature search strategy
--------------------------

This systematic review was performed according to the preferred reporting items for systematic reviews and meta-analysis statement\[[@B13]\]. A thorough search of the literature was conducted in the PubMed database to identify articles that described the use of OTSC for any GI indication from January 1, 2007 to January 15, 2020. The search was performed using the following terms: "over-the-scope-clip", "OTSC", "endoscopic fistula closure," "over-the-scope clip bleeding", "stent fixation", and "endoscopic perforation closure."

Eligibility criteria
--------------------

All English-language abstracts and/or full-text articles reporting original data of OTSC use (in humans, only) for the indication of fistulae, perforation, anastomotic leak closure, GI hemorrhage, endoscopic resection, and stent fixation were reviewed (authors: Bartell N and Bittner K) to assess eligibility for inclusion. Case reports and case series with fewer than five patients were excluded. Articles were also omitted if reported data did not include the rate of clinical success.

Data extraction, outcomes and statistical analysis
--------------------------------------------------

Data extraction included the following: Author(s), year of publication, study type/design, location(s), number of patients, indication(s) for OTSC use, clinical and technical success rates (TSR), duration of follow-up, and OTSC-related AEs. The primary outcome of interest was clinical success rate (CSR). Secondary outcomes included TSR, requirement for surgical intervention despite OTSC, and reported OTSC-related AEs. Pooled rates (per-indication and overall) were calculated as the number of patients with the event of interest divided by the total number of patients.

Definitions
-----------

CSR was defined as complete and durable resolution of the respective defect, hemorrhage and/or stent fixation. TSR was defined as the successful deployment of the OTSC clip to the targeted lesion or defect. OTSC-related AEs were defined as unanticipated events probably or possibly directly related to the use of the OTSC clip.

RESULTS
=======

Primary and secondary outcomes
------------------------------

A total of 512 record matches were located in the PubMed database, per the literature search strategy. Two authors (Bartell N and Bittner K) reviewed each title, abstract and/or full-text article prior to applying the full exclusion criteria. A total of 109 publications were retrieved for full review, with 24 excluded from the final analysis (Figure [3](#F3){ref-type="fig"}). Eighty-five articles\[[@B2]-[@B6],[@B14]-[@B92]\] (Table [2](#T2){ref-type="table"}) met inclusion criteria (*n* = 3025 patients). Indications for OTSC use included: Fistulae (*n* = 622), GI hemorrhage (*n* = 1303), perforation (*n* = 468), anastomotic leak closure (*n* = 391), endoscopic resection defect closure (*n* = 221), and stent fixation (*n* = 20). The overall CSR (inclusive of all indications) and TSR for OTSC placement was 78.4% (*n* = 2371/3025) and 94.4% (*n* = 2856/3025), respectively. Per-indication CSR, TSR, and post-OTSC surgery rates are described in Table [3](#T3){ref-type="table"}.

###### 

Summary of included studies (overall clinical success rate, per-indication clinical success rate, and overall over-the-scope clip-related adverse event rate)

  **Ref**.                            **Year**    **Type of study**              **Country**                                       **Patients (*n*)**   **Overall clinical success rate (%)**   **Follow-up (wk)**   **Adverse events,** ***n* (%)**                                                                                
  ----------------------------------- ----------- ------------------------------ ------------------------------------------------- -------------------- --------------------------------------- -------------------- --------------------------------- ------------------------------------------- ------ ------ ------ ----------- ----------
  Seebach et al\[[@B15]\]             2010        Case series Retrospective      Switzerland                                       7                    \-                                      \-                   57.1                              \-                                          \-     \-     57.1   10-42       NR
  Kirschniak et al\[[@B2]\]           2007        Retrospective                  Germany                                           11                   \-                                      100                  100                               \-                                          100    \-     100    1-5         0.0
  Mudumubi et al\[[@B16]\]            2014        Retrospective                  International[1](#T2FN1){ref-type="table-fn"}     12                   \-                                      \-                   \-                                \-                                          \-     83.3   83.3   3-40        0.0
  Sandmann et al\[[@B17]\]            2011        Case series Retrospective      Germany                                           11                   100                                     \-                   100                               66                                          100    \-     90.9   12.7        NR
  Albert et al\[[@B18]\]              2011        Retrospective                  Germany                                           19                   \-                                      57.1                 \-                                66.7                                        \-     \-     63.2   1-68        0.0
  Repici et al\[[@B19]\]              2009        Case series Retrospective      Italy                                             9                    \-                                      100                  \-                                \-                                          100    \-     100    4-12        0.0
  Donatelli et al\[[@B20]\]           2016        Retrospective                  International[2](#T2FN2){ref-type="table-fn"}     45                   36.7                                    \-                   100                               \-                                          \-     \-     57.8   36-100      0.0
  Maekawa et al\[[@B21]\]             2015        Prospective                    Japan                                             12                   \-                                      \-                   \-                                \-                                          91.7   \-     91.7   NR          0.0
  Gautier et al\[[@B22]\]             2015        Retrospective Multi-center     France                                            17                   11.8                                    \-                   \-                                \-                                          \-     \-     11.8   12          NR
  Nishiyama et al\[[@B23]\]           2013        Retrospective                  Japan                                             23                   75                                      77.8                 75                                \-                                          100    \-     82.6   2-8         0.0
  Voermans et al\[[@B24]\]            2012        Prospective Multi-center       Netherlands                                       36                   \-                                      \-                   88.9                              \-                                          \-     \-     88.9   1-26        0.0
  Lee et al\[[@B26]\]                 2017        Prospective Multi-center       Korea                                             19                   25                                      \-                   100                               83.3                                        100    \-     73.7   72          0.0
  Angsuwatcharakon et al\[[@B27]\]    2016        Retrospective                  Thailand                                          6                    \-                                      \-                   83.3                              \-                                          \-     \-     83.3   NR          NR
  Arezzo et al\[[@B28]\]              2012        Case series Prospective        Italy                                             14                   \-                                      \-                   \-                                85.7                                        \-     \-     85.7   16          0.0
  Schlag et al\[[@B29]\]              2013        Prospective                    Germany                                           6                    \-                                      \-                   100                               \-                                          \-     \-     100    4-12        0.0
  Disibeyaz et al\[[@B30]\]           2012        Case series Retrospective      Turkey                                            9                    33.3                                    \-                   100                               60                                          \-     \-     55.6   NR          0.0
  Gubler et al\[[@B31]\]              2012        Case series Prospective        Switzerland                                       14                   \-                                      \-                   85.7                              \-                                          \-     \-     85.7   4-48        NR
  Singhal et al\[[@B32]\]             2014        Case Series Prospective        United States                                     10                   90                                      \-                   \-                                \-                                          \-     \-     90     7           0.0
  Mennigen et al\[[@B33]\]            2013        Case series Retrospective      Germany                                           14                   71.4                                    \-                   100                               83.3                                        \-     \-     78.6   1-68        0.0
  Faehndrich et al\[[@B34]\]          2015        Retrospective                  Germany                                           17                   \-                                      \-                   \-                                \-                                          94.1   \-     94.1   NR          0.0
  Schmidt et al\[[@B4]\]              2015        Prospective Multi-center RCT   International[3](#T2FN3){ref-type="table-fn"}     24                   \-                                      \-                   \-                                \-                                          75     \-     75     4           2 (8.3)
  Guo et al\[[@B35]\]                 2015        Retrospective                  China                                             23                   \-                                      \-                   \-                                \-                                          100    \-     100    4-24        2 (8.7)
  Correia et al\[[@B36]\]             2014        Case series Prospective        Portugal                                          6                    80                                      \-                   100                               \-                                          \-     \-     83.3   NR          0.0
  Goenka et al\[[@B37]\]              2017        Prospective                    India                                             12                   66                                      100                  100                               \-                                          \-     \-     91.7   4-8         0.0
  Surace et al\[[@B38]\]              2011        Prospective                    Italy                                             19                   73.7                                    \-                   \-                                \-                                          \-     \-     73.7   32          1 (5.3)
  Kochhar et al\[[@B39]\]             2017        Case series Prospective        United States                                     12                   \-                                      \-                   \-                                66.7                                        \-     \-     66.7   60          1 (8.3)
  Manta et al\[[@B40]\]               2017        Prospective                    Italy                                             76                   \-                                      \-                   \-                                80.3                                        \-     \-     80.3   NR          0.0
  Parodi et al\[[@B41]\]              2010        Prospective                    Italy                                             10                   80                                      \-                   100                               50                                          \-     \-     80.0   NR          0.0
  Manta et al\[[@B42]\]               2011        Case series Retrospective      Italy                                             12                   87.5                                    \-                   \-                                75                                          \-     \-     83.3   4           0.0
  Honegger et al\[[@B43]\]            2017        Retrospective Cohort           Switzerland                                       203                  29.8                                    77.4                 86.1                              33.3                                        \-     66.7   63.1   4           6 (3.0)
  Manno et al\[[@B44]\]               2015        Retrospective                  International[4](#T2FN4){ref-type="table-fn"}     40                   \-                                      100                  \-                                \-                                          \-     \-     100    4           0.0
  Richter-Schrag et al\[[@B45]\]      2016        Retrospective                  Germany                                           100                  \-                                      78                   \-                                \-                                          \-     \-     78     NR          NR
  Aepli et al\[[@B46]\]               2016        Retrospective                  Switzerland                                       24                   \-                                      \-                   \-                                \-                                          87.5   \-     87.5   NR          4 (16.7)
  Law et al\[[@B48]\]                 2015        Retrospective Multi-center     United States                                     47                   53.2                                    \-                   \-                                \-                                          \-     \-     53.2   26          0.0
  Farnik et al\[[@B3]\]               2015        Retrospective Multi-center     International[5](#T2FN5){ref-type="table-fn"}     34                   \-                                      \-                   100                               56.3                                        \-     \-     70.5   39          0.0
  Jacobsen et al\[[@B49]\]            2012        Retrospective                  United States                                     10                   0                                       \-                   100                               80                                          \-     \-     70.0   12          0.0
  Haito-Chavez et al\[[@B50]\]        2014        Retrospective Multi-center     International[6](#T2FN6){ref-type="table-fn"}     161                  42.9                                    \-                   90                                73.3                                        \-     \-     60.2   18 -- 30    0.0
  Winder et al\[[@B51]\]              2016        Retrospective                  United States                                     28                   77.2                                    \-                   \-                                100                                         \-     \-     82.1   19          0.0
  Sulz et al\[[@B52]\]                2014        Case series Prospective        Switzerland                                       19                   54.5                                    100                  \-                                66.7                                        \-     100    63.1   NR          0.0
  Magdeburg et al\[[@B53]\]           2015        Prospective                    Germany                                           43                   \-                                      \-                   97.8                              \-                                          \-     \-     97.8   NR          3 (7.0)
  Wedi et al\[[@B54]\]                2016        Retrospective                  France                                            84                   100                                     89.3                 57.1                              \-                                          100    \-     89.3   NR          2 (2.4)
  Keren et al\[[@B55]\]               2014        Case series Prospective        Israel                                            26                   \-                                      \-                   \-                                80.8                                        \-     \-     80.8   NR          0.0
  Raithel et al\[[@B14]\]             2017        Retrospective Multi-center     Germany                                           34                   \-                                      \-                   74.1                              85.7                                        \-     \-     76.5   NR          3 (8.8)
  Kobara et al\[[@B56]\]              2017        Retrospective Multi-center     Japan                                             58                   83.3                                    83.3                 \-                                85.7                                        \-     \-     84.5   4+          1 (1.8)
  Hagel et al\[[@B57]\]               2012        Case series Prospective        Germany                                           17                   \-                                      \-                   64.7                              \-                                          \-     \-     64.7   4           NR
  Nasa et al\[[@B58]\]                2016        Case series Retrospective      India                                             7                    80                                      100                  100                               \-                                          \-     \-     85.7   45          NR
  Skinner et al\[[@B6]\]              2014        Retrospective                  United States                                     12                   \-                                      83.3                 \-                                \-                                          \-     \-     83.3   10 -- 30    0.0
  Al-Bawardy et al\[[@B59]\]          2017        Retrospective                  United States                                     7                    \-                                      \-                   \-                                \-                                          100    \-     100    1 -- 86     0.0
  Sarker et al\[[@B60]\]              2014        Retrospective                  United States                                     8                    \-                                      \-                   \-                                \-                                          100    \-     100    4 -- 52     0.0
  Mangiavillano et al\[[@B61]\]       2016        Retrospective                  Italy                                             20                   \-                                      \-                   90                                \-                                          \-     \-     90     12          NR
  Aiolfi et al\[[@B62]\]              2014        Retrospective                  Italy                                             7                    \-                                      \-                   \-                                85.7                                        \-     \-     85.7   NR          NR
  Manta et al\[[@B5]\]                2013        Case series Multi-center       Italy                                             30                   \-                                      90                   \-                                \-                                          \-     \-     90     1 -- 4      0.0
  Mangiafico et al\[[@B63]\]          2017        Case series Prospective        International[7](#T2FN7){ref-type="table-fn"}     7                    100                                     \-                   \-                                \-                                          \-     \-     100    2 -- 8      0.0
  Niland et al\[[@B64]\]              2017        Retrospective                  United States                                     14                   21.4                                    \-                   \-                                \-                                          \-     \-     21.4   26          0.0
  Schmdtt et al\[[@B4]\]              2018        Prospective RCT                International[8](#T2FN8){ref-type="table-fn"}     33                   \-                                      84.8                 \-                                \-                                          \-     \-     84.8   4           0.0
  Heinrich et al\[[@B65]\]            2017        Case series Retrospective      Switzerland                                       5                    100                                     \-                   \-                                \-                                          \-     \-     100    46 -- 269   0.0
  Prosst et al\[[@B66]\]              2015        Prospective                    Germany                                           20                   90                                      \-                   \-                                \-                                          \-     \-     90     24          0.0
  Mizrahi et al\[[@B67]\]             2016        Prospective                    United States                                     51                   35.3                                    75                   75                                50                                          \-     50     49.0   48          NR
  Kirschniak et al\[[@B68]\]          2011        Retrospective                  Germany                                           46                   37.5                                    93                   100                               \-                                          \-     \-     84.8   1 -- 2      0.0
  Mennigen et al\[[@B69]\]            2015        Retrospective                  Germany                                           10                   70                                      \-                   \-                                \-                                          \-     \-     70     22 -- 75    0.0
  Wedi et al\[[@B70]\]                2016        Retrospective Case series      International[9](#T2FN9){ref-type="table-fn"}     6                    \-                                      100                  \-                                \-                                          \-     \-     100    NR          NR
  Baron et al\[[@B71]\]               2012        Retrospective Multi-center     United States                                     43                   67.9                                    100                  80                                33.3                                        \-     \-     72.1   4 -- 11     2 (4.7)
  Lamberts et al\[[@B72]\]            2017        Retrospective                  Germany                                           75                   \-                                      65.3                 \-                                \-                                          \-     \-     65.3   NR          NR
  Soetikno et al\[[@B73]\]            2016        Case series Retrospective      International[10](#T2FN10){ref-type="table-fn"}   5                    \-                                      100                  \-                                \-                                          \-     \-     100    60          0.0
  Wedi et al\[[@B74]\]                2017        Retrospective                  International[11](#T2FN11){ref-type="table-fn"}   100                  \-                                      86                   \-                                \-                                          \-     \-     73     NR          NR
  Chan et al\[[@B75]\]                2014        Case series Prospective        China                                             9                    \-                                      77.8                 \-                                \-                                          \-     \-     77.8   8           NR
  Keen et al\[[@B76]\]                2019        Prospective                    United Kingdom                                    59                   \-                                      93.2                 \-                                \-                                          \-     \-     93.2   4           NR
  Horenkamp-Sonntag et al\[[@B77]\]   2019        Retrospective                  Germany                                           92                   \-                                      82.4                 87.9                              \-                                          \-     \-     92.4   14          NR
  Manta et al\[[@B78]\]               2019        Retrospective Multi-center     Italy                                             286                  \-                                      94.4                 \-                                \-                                          \-     \-     94.4   4           NR
  Mercky et al\[[@B79]\]              2015        Retrospective                  France                                            30                   73.3                                    \-                   \-                                \-                                          \-     \-     73.3   42          3 (10)
  Monkemuller et al\[[@B80]\]         2014        Case series Retrospective      Germany                                           16                   50                                      100                  \-                                0                                           100    100    75     44          0.0
  Bonino et al\[[@B81]\]              2014        Case series Prospective        Italy                                             26                   90                                      \-                   68.8                              \-                                          \-     \-     76.9   NR          0.0
  Christophorou et al\[[@B82]\]       2015        Retrospective Multi-center     France                                            14                   78.5                                    \-                   \-                                \-                                          \-     \-     78.5   NR          NR
  Lunse et al\[[@B83]\]               2019        Retrospective                  Germany                                           9                    66.7                                    \-                   \-                                \-                                          \-     \-     66.7   8           0.0
  Mosquera-Klinger et al\[[@B84]\]    2019        Retrospective Case series      Columbia                                          14                   70                                      100                  100                               \-                                          \-     100    78.6   20          0.0
  Brander et al\[[@B25]\]             2017        Retrospective                  United States                                     67                   \-                                      70.1                 \-                                \-                                          \-     \-     70.1   4           NR
  Meier et al\[[@B47]\]               2017        Retrospective                  Germany                                           10                   \-                                      \-                   \-                                \-                                          100    \-     100    12          0.0
  Tashima et al\[[@B85]\]             2017        Prospective                    Japan                                             50                   \-                                      \-                   \-                                \-                                          94     \-     94     2           4 (8)
  Khater et al\[[@B86]\]              2017        Retrospective                  France                                            11                   \-                                      \-                   81.2                              \-                                          \-     \-     81.2   NR          1 (9)
  Asokkumar et al\[[@B87]\]           2018        Retrospective                  International[12](#T2FN12){ref-type="table-fn"}   19                   \-                                      100                  \-                                \-                                          \-     \-     100    NR          0.0
  Morrell et al\[[@B88]\]             2019        Retrospective                  United States                                     117                  50.8                                    \-                   \-                                75                                          \-     \-     61.2   22          0.0
  Kappelle et al\[[@B89]\]            2018        Prospective                    Netherlands                                       13                   \-                                      \-                   \-                                \-                                          84.6   \-     84.6   24          5 (38.4)
  Wei et al\[[@B90]\]                 2019        Retrospective                  China                                             26                   \-                                      \-                   100                               \-                                          \-     \-     100    4           0.0
  Golder et al\[[@B91]\]              2019        Retrospective                  Germany                                           100                  \-                                      75                   \-                                \-                                          \-     \-     75     NR          0.0
  Wedi et al\[[@B92]\]                2018        Retrospective Multi-center     Germany                                           118                  \-                                      92.4                 \-                                \-                                          \-     \-     92.4   4           NR
  Total                               3025        55.8%                          86.0%                                             85.3%                72.6%                                   92.8%                80.0%                             78.4%                                       \-     2.1%                      
  347/622                             1120/1303   399/468                        284/391                                           205/221              16/20                                   2371/3025            \-                                40/1942[13](#T2FN13){ref-type="table-fn"}                                    

Germany, United States.

France, Italy, India.

Switzerland, Germany.

Italy, United Kingdom.

Germany, Japan.

United States, Italy, Germany, Netherlands, Chile.

Italy, United Kingdom.

Germany, China, Switzerland.

Germany, France, Canada, United States.

United States, Singapore.

Germany, France, Canada, United States.

Singapore, Spain.

Over the scope clip-related adverse events were only reported for 1958 of 3041 patients (*n* = 65 studies). NR: Not reported; ER: Endoscopic resection; RCT: Randomized control trial.

###### 

Over-the-scope clip-related adverse events, per-indication

                   **Incorrect placement site**   **Perforation**                     **Bleeding**   **Infection**   **Overall**
  ---------------- ------------------------------ ----------------------------------- -------------- --------------- ------------------------------------
  Fistula          0                              3                                   0              2               5
  Bleeding         0                              0                                   0              0               0
  Perforation      2                              2[2](#T3FN2){ref-type="table-fn"}   2              1               7
  Leak             1                              1                                   0              1               3
  ER               4                              2                                   7              6               19
  Stent fixation   0                              0                                   0              0               0
  Total            7                              8                                   9              10              34[1](#T3FN1){ref-type="table-fn"}

The total number of Over the scope clip-related adverse events recorded was 40; however, one article (Honegger et al\[[@B41]\]) did not report adverse events per-indication and thus cannot be included in this table. A total of six such events occurred, including: incorrect placement site (*n* = 4), perforation (*n* = 1) and bleeding (*n* = 1);

Adverse events for the initial indication of perforation are defined as exacerbation or worsening of the index perforation qualifying as a separate adverse event. ER: Endoscopic resection.

![Article selection process, per preferred reporting items for systematic reviews and meta-analysis guideline.](WJG-26-3495-g003){#F3}

GI hemorrhage
-------------

Endoscopic management of GI hemorrhage is well-established, with a number of available modalities to effectively achieve mechanical or coagulative hemostasis. Conventional endoscopic techniques are successful in managing GI hemorrhage in most cases; however, the rate of re-bleeding has been reported at 10%-20%\[[@B93]\]. Patients presenting with a re-bleed often require repeat endoscopic intervention, angiography (interventional radiology), or definitive management with surgery\[[@B93]\]. Mechanical hemostasis is often attempted with TTS clips which can be effective for smaller lesions; however, large and/or complex lesions may require a clip with larger diameter (up to 14 mm) and more tensile strength to achieve effective hemostasis.

In current endoscopic practice, OTSC is mainly used in refractory bleeding cases (Figure [4](#F4){ref-type="fig"}) following a failure of conventional therapy; however, a head-to-head randomized control trial (RCT) is currently being conducted in Europe (ClinicalTrials.gov, NCT03551262) to evaluate its efficacy as a potential primary therapy for hemostasis. Manno et al\[[@B44]\] retrospectively reviewed 40 consecutive cases of high-risk non-variceal upper GI hemorrhage utilizing OTSC as a primary intervention. The authors reported a CSR of 100%, with no OTSC-related AEs (30-d follow up). In 2017, Wedi et al\[[@B74]\] highlighted the efficacy of OTSC in a retrospective review of 100 high-risk patients presenting with non-variceal upper GI bleeding. In this cohort, most (51%) of patients had severe cardiovascular comorbidities, with the majority (73%) on an antiplatelet regimen, thus potentially precluding a surgical approach in these patients. This article reported a CSR of 86% at 6 months of follow-up. In a subsequent study, Wedi et al\[[@B92]\] compared OTSC to standard of care treatment in non-variceal upper GI bleeding demonstrating superiority of OTSC, especially in high-risk patients. Specifically, patients with Rockall scores ≥ 8 showed significantly lower rates of re-bleeding when treated with OTSC as a first-line therapy as compared to patients treated with conventional modalities (10.9% *vs* 27.9%, respectively)\[[@B92]\]. Thus, OTSC can be used as the primary modality in high-risk patients such as those on anticoagulation, bleeding from large caliber vessels, or if they are not a good surgical candidate and/or as a rescue treatment for re-bleeding when conventional hemostasis options fail.

![Over the scope clip used in management of gastrointestinal bleeding. A: Massive gastrointestinal bleeding from duodenal bulb ulcer with an actively bleeding blood vessel; B: Successful hemostasis achieved using over-the-scope-clip.](WJG-26-3495-g004){#F4}

In our systematic review, the overall CSR and TSR for the indication of GI hemorrhage was 86.0% and 96.8%, respectively. Surgical intervention for control of GI hemorrhage following OTSC placement was only required in 1.6% (21/1303) of patients.

Perforation
-----------

Though infrequent, perforation is an established risk of any endoscopic procedure, with average rates from 1 in 2500 to 1 in 11000 esophagogastroduodenoscopy's and 5.8 per 10000 for colonoscopy\[[@B94]-[@B96]\]. Advanced endoscopic interventions (including resection), have a higher risk of perforation than diagnostic procedures. Conventional management of acute iatrogenic perforation often necessitates surgical intervention; however, an effective and minimally invasive endoscopic approach to close these lesions during the index procedure is preferential to a higher-morbidity surgical intervention. Several endoscopic interventions have been utilized to manage perforations with varying degrees of success including: Self-expanding metal stents (SEMSs), TTS clips, endoscopic suturing, and OTSC\[[@B97]\]. SEMSs have been primarily used in the management of esophageal perforation; however, they carry the risk of migration and incomplete seal. TTS clips have limited ability to achieve complete closure of large defects and endoscopic suturing is limited by operator expertise, tedium and endoscope length in cases of perforation in the small bowel. Endoscopic suturing can also be challenging when managing defects in difficult locations such as gastric cardia, esophagus, duodenum, and proximal colon.

The European Society of GI Endoscopy currently recommends that endoscopic closure of iatrogenic perforations be considered during the index procedure\[[@B97]\]. OTSC is advantageous in this setting, as its ease of use, ability to close defects between 1-3 cm with a single clip application, and safety profile allow the endoscopist to effectively manage acute perforation immediately upon recognition (Figure [5](#F5){ref-type="fig"})\[[@B97]\]. If the attempt to close perforation is delayed (\> 72 h) or the defect is larger than 2 cm in diameter, endoscopic management is more likely to fail; however, the TG device can be utilized to approximate the edges of the defect for more effective closure with the OTSC, when dealing with larger defects (\> 2 cm)\[[@B57],[@B97]\]. Additionally, in cases of esophageal perforation, closure may be difficult with only suctioning the defect into the applicator cap (given the tangential orientation of the esophageal wall of to the endoscope). In this instance, the TG can help grasp the tissue to facilitate closure of the defect. Caution should be exercised while deploying the OTSC in difficult locations (*e.g*., gastro-esophageal junction, pylorus and the duodenal sweep) to avoid closing off the lumen entirely.

![Over the scope clip used in management of gastrointestinal perforation. A: Gastro-esophageal junction perforation caused during advancement of side viewing duodenoscope; B: Successful closure of perforation using over-the-scope-clip.](WJG-26-3495-g005){#F5}

Honegger et al\[[@B43]\] reported on the efficacy of OTSC in a large cohort of patients (*n* = 72) with iatrogenic endoscopic perforations, with a stated CSR of 86.1%. Two patients experienced OTSC-related AEs, with one case of bleeding and one with a worsening of the index perforation. In a recent study, Wei et al\[[@B90]\] described the use of OTSC in patients with perforated peptic ulcer compared to a control group that was managed conventionally. The rate of clinical success in the OTSC group was 100% (*n* = 26/26) *vs* only 57.5% (*n* = 46/80) in controls. The requirement for surgical intervention in the OTSC cohort was significantly lower than controls (0% *vs* 30.0%, respectively, *P* \< 0.001). No OTSC-related AEs were reported\[[@B90]\].

In our systematic review the overall CSR and TSR for the indication of perforation was 85.3% and 95.5%, respectively. Surgical intervention post-OTSC placement was required to achieve complete closure in 9.4% (*n* = 44/468) of patients.

Defect closure following endoscopic resection
---------------------------------------------

Prior to the availability of OTSC, prophylactic closure of defects created by endoscopic resection of GI lesions would be managed with TTS clips. Prophylactic TTS clip closure following the resection of large (\> 1 cm) proximal colonic lesions is an effective strategy that has reduced the incidence of post-procedure AEs (including post-polypectomy hemorrhage) and increased patient satisfaction\[[@B98]-[@B100]\]; however, TTS are limited by their diameter and often require a "suturing" technique involving the placement of multiple clips across the lesion. With the deployment of OTSC, a defect of 1-3 cm in diameter can be successfully closed utilizing a single clip\[[@B98]\].

The full-thickness resection device (FTRD; Ovesco Endoscopy AG, Tübingen, Germany) is now commercially available. This accessory combines the ability to complete resection and clipping with a single device. Aepli et al\[[@B46]\] reported the first clinical data in 2016 on the use of FTRD, demonstrating a CSR (*n* = 24 patients) of 87.5% and a post-OTSC AE rate of 12.5% (*n* = 4/24) with 3 post-procedure bleeding events and one post procedure perforation.

In our systematic review the overall CSR and TSR for the indication of defect closure following endoscopic resection was 92.8% and 95.9%, respectively. The necessity for post-OTSC surgical intervention was rare (*n* = 2/221; 0.9%).

Fistula closure
---------------

GI fistulae are difficult to manage with either endoscopic or surgical interventions, likely due to the chronicity of the problem, fibrotic non healing tracts and prior treatment attempts making subsequent closure increasingly difficult. In addition, the underlying pathogenesis combined with a presentation of impaired nutritional status contribute to slow or non-healing of the fistula. Conventional management of GI fistulae focuses on control/prevention of infection, optimization of nutrition/ hydration, and limiting of fistula output. Surgical management can be attempted as a definitive therapy in lower-risk patients; however, patients with complex fistulae may be too medically frail for surgical intervention and/or those presenting with a small bowel fistula may not have enough remnant bowel to allow for further resection.

In recent years, endoscopy been considered as a possible primary therapy for the closure of GI fistulae\[[@B101]\]. Prior to the advent of OTSC, endoscopic treatment of GI fistulae had been attempted with TTS, absorbable loop snares or glues to varying degrees of success\[[@B102]\]. OTSC has potential in the management of GI fistulae (Figure [6](#F6){ref-type="fig"}), as the suction utilized in the clip application can create a more robust closure than TTS; however, definitive closure of a fistula relies on the complete grasping of involved tissue within the clipping device, which may be difficult when fibrotic tissue is present, as in most fistulae. High rates of clinical success for fistula closure have not yet been reported with OTSC. Haito-Chavez et al\[[@B50]\] reported the largest study of OTSC use in patients with fistulae (*n* = 91 patients) secondary to percutaneous endoscopic gastrostomy or jejunostomy tubes, post-bariatric surgery, malignancy-related, trauma, inflammatory bowel disease or diverticulitis. Deployment of the OTSC was successful in 89.4% of patients; however, clinical success at a median of 121 d was only 42.9%\[[@B50]\]. Other studies have reported similar CSR for fistula closure with OTSC\[[@B48]\]. Haito-Chavez et al\[[@B50]\] discuss the likelihood that fistulae with fibrotic and retracted rims were most associated with clinical failure, possibly related to the difficulty in properly targeting and suctioning the tissue during OTSC application. Fistulae smaller than 1 cm could be considered for closure with OTSC; however, in cases with a large fistula (\> 1 cm) more than one clip could be applied and/or utilized in combination with endoscopic suturing with reinforced OTSC or glue to successfully achieve closure.

![Over the scope clip used in management of gastrointestinal fistula. A: Gastro-gastric fistula in a patient with Roux-en-Y gastric bypass; B: Argon plasma coagulation ablation of the fistula margin; C: Successful closure of fistula using over-the-scope-clip.](WJG-26-3495-g006){#F6}

In our systematic review the overall CSR and TSR for the indication of fistulae was 55.8% and 92.8%, respectively. Surgical intervention post-OTSC placement was required in 7.6% (*n* = 47/622) of patients.

Closure of anastomotic leaks
----------------------------

Conventional management for anastomotic leaks often follows a conservative approach of broad-spectrum antibiotics for lower-risk lesions and/or repeated surgical intervention for higher-risk lesions. The probability of a post-surgical anastomotic leak is higher in patients with a low serum albumin, longer operative time, higher intraoperative blood loss, positive resection margins or the presence of inflammatory bowel disease\[[@B103]\]. An effective minimally invasive endoscopic approach is preferable, as many of these patients may be too high-risk for additional surgical intervention.

Manta et al\[[@B42]\] presented the largest case series of patients (*n* = 76) with anastomotic leaks included in this review. Post-surgical leaks appeared in both the upper (*n* = 47) and lower (*n* = 29) GI tract. Overall clinical success was achieved in 80.3% of patients (83% and 75.9% for upper and lower GI leaks, respectively)\[[@B42]\].

In our systematic review the overall CSR and TSR for the indication of anastomotic leak closure was 72.6% and 86.7%, respectively. Surgical intervention post-OTSC placement was required in 7.4% (29/391) of patients.

Stent fixation
--------------

GI stenting (most often for tumor palliation) though effective in immediate symptomatic relief, is often plagued by stent migration, especially in the case of fully covered stents\[[@B104]\]. The availability of SEMSs has reduced the risk of migration; however, the potential still exists\[[@B105]\]. OTSC can be used to anchor SEMS to mitigate the risk of stent migration. Limited data exist on the application of OTSC in this setting. The largest paper in the literature was presented by Mudumbi et al\[[@B16]\], demonstrating a high CSR (83%) in 12 patients who underwent OTSC fixation of SEMS, with no reported OTSC-related AEs. If it is necessary to remove a stent anchored by OTSC, the clip itself will need to be detached to do so, which is neither easy nor predictable. Traditionally, the only feasible method to remove the OTSC was with argon plasma coagulation; however, a novel device (remOVE system; Ovesco Endoscopy AG, Tubingen, Germany) has since been developed to effectively detach the OTSC\[[@B106],[@B107]\].

In our systematic review the overall CSR and TSR for the indication of stent fixation was 80.0% and 100%, respectively; however, only 20 patients were included due to the paucity of data regarding OTSC for stent fixation in the literature. No patients required surgical intervention following OTSC placement or as a result of removal.

OTSC-related AEs
----------------

Sixty-four studies (*n* = 1942 patients) reported OTSC-related AE data (Table [4](#T4){ref-type="table"}), with an overall rate of 2.1% (*n* = 40/1,942). These events included: "incorrect placement site" (*n* = 11/40; 27.5%), perforation (*n* = 9/40; 22.5%), bleeding (*n* = 10/40; 25%), and infection (*n* = 10/40; 25%). No deaths occurred as a result of OTSC use.

###### 

Per-indication clinical success rate, technical success rate, and post-over-the-scope clip surgery rates

                   **Clinical success rate (%), (*n*/*N*)**   **Technical success rate (%), (*n*/*N*)**   **Post-over the scope clip surgical rate (%), (*n*/*N*)**
  ---------------- ------------------------------------------ ------------------------------------------- -----------------------------------------------------------
  Fistula          55.8 (347/622)                             92.8 (577/622)                              7.6 (47/622)
  Bleeding         86.0 (1120/1303)                           96.8 (1261/1303)                            1.6 (21/1303)
  Perforation      85.3 (399/468)                             95.5 (447/468)                              9.4 (44/468)
  Leak             72.6 (284/391)                             86.7 (339/391)                              7.4 (29/391)
  ER               92.8 (205/221)                             95.9 (212/221)                              0.9 (2/221)
  Stent fixation   80.0 (16/20)                               100 (20/20)                                 0.0 (0/20)
  Overall          78.4 (2371/3025)                           94.4 (2856/3025)                            4.7 (143/3025)

ER: Endoscopic resection.

A perforation was defined as an AE if the OTSC: (1) Caused a de novo perforation, or (2) Worsened an already existing perforation that the OTSC was intended to close. "Incorrect placement site" was defined as the placement of the OTSC in a location other than the targeted defect and/or the disruption of nearby tissue/structures by the OTSC. For instance, Honegger et al\[[@B43]\] reported three cases of inadvertent OTSC deployment on the tongue during withdrawal of the endoscope and one case of OTSC deployment in the rectum causing a pseudopolyp formation resulting in a clinically significant obstruction. Raithel et al\[[@B14]\] reported a case of colonic perforation managed with OTSC resulting in fixation of the small bowel to the colon and subsequent rupture of the small bowel requiring surgical intervention. Khater et al\[[@B86]\] further described the potential of the OTSC to disrupt nearby tissue/structures reporting a case of rectosigmoid perforation that was effectively closed with OTSC; however, follow-up imaging studies demonstrated dilation of the urinary tract and ureter obstruction as a result of the ureter being suctioned into the application cap during clip deployment. Ultimately this patient required surgical intervention\[[@B86]\]. Such cases highlight the potential hazards and drawbacks related to the application of the OTSC clip, therefore careful consideration of surrounding anatomy should be entertained prior to OTSC deployment. Though the incorrect placement of OTSC can be a significant AE (due to difficulty in OTSC removal), the remOVE device is now available to detach the OTSC if placement of the clip is not satisfactory. Preliminary data suggest successful fragmentation of the OTSC with remOVE in 97.3% of cases, with minimal AEs (bleeding in 2.7% of patients, and superficial mucosal tearing in 1.4% of patients)\[[@B107]\].

DISCUSSION
==========

To our knowledge, this systematic review represents the most comprehensive data (3025 cases over a period of 12 years; 2007-2019) of OTSC use across all GI indications. A high CSR (\> 75%) was reported in the majority of clinical applications of OTSC. Our review confirms the efficacy of OTSC in preventing surgical intervention in most cases, as only 4.7% (*n* = 143/3025) of patients required salvage surgery, despite OTSC placement. OTSC can be considered for patients that are too high-risk for surgery but who can still tolerate endoscopy. OTSC facilitates effective endoscopic management of iatrogenic complications and known complex defects that previously may have only been amenable to surgical repair.

When each indication for OTSC placement is evaluated individually, there are clear disparities in CSRs for certain indications. A CSR of greater than 85% was observed in the management of GI hemorrhage, perforation and defect closure following endoscopic resection with OTSC; however, fistula closure was comparatively much less successful with a CSR of 55.8%. The lower efficacy of OTSC in fistula closure compared to other indications is thought to be multifactorial from the chronicity of the underlying problem and other variables discussed above that can make subsequent closure attempts challenging. Further innovation in technology and accessories can help close this gap in effectiveness across various indications and improve the effectiveness of OTSC in challenging scenarios.

In one of the earlier published articles on OTSC, Seebach et al\[[@B15]\] noted that OTSC has the potential to "spare the surgeon". Our review strengthens this opinion as there was no indication for OTSC placement in which a rate of post-OTSC surgery was greater than 10%. Prior to the use of OTSC, surgical intervention would have been required for most of the patients included in this review. The rates of surgery, and the AEs, morbidity and mortality associated with it, will decrease for patients as OTSC becomes more integrated into routine endoscopic practices. Furthermore, patients who previously were deemed to be poor surgical candidates may now be able to be successfully managed with a less invasive and effective endoscopic approach.

The main limitation of this review is the level of available evidence related to OTSC use, as there is a paucity of RCTs or large multi-center analyses in the literature. The majority of articles include a relatively small sample size and/or are a summation of a single-center's experience with OTSC use across multiple indications. In addition, our review lacks a large cohort of patients that underwent OTSC placement following endoscopic resection or for stent fixation. The potential for selection bias in pooling results from case series or single-center retrospective studies is acknowledged. Case series are often likely to underrepresent AEs and negative outcomes, as often authors are interested in adding positive results to the literature. Our review attempted to limit this bias by including studies with five or more patients. When isolating studies with a prospective design only (Table [5](#T5){ref-type="table"}), a similar overall CSR and OTSC-related AE rate was demonstrated, suggesting that pooled retrospective data may be truly representative of the efficacy and safety of OTSC. The potential for lack of generalizability to a community setting may exist due to the likelihood that the majority of endoscopists currently utilizing OTSC in their practice are considered "experts" and/or performing some level of advanced endoscopic procedures.

###### 

Summary of prospective studies (overall clinical success rate, per-indication clinical success rate and adverse event rate)

  **Ref**.                     **Year**   **Type of study**              **Country**                                     **Patients (*n*)**   **Overall clinical success rate (%)**   **Follow-up (wk)**   **Adverse events, *n* (%)**                                                                          
  ---------------------------- ---------- ------------------------------ ----------------------------------------------- -------------------- --------------------------------------- -------------------- ----------------------------- ---------------------------------------- ------- ------ ------- ------ ----------
  Maekawa et al\[[@B21]\]      2015       Prospective                    Japan                                           12                   \-                                      \-                   \-                            \-                                       11/12   \-     11/12   NR     0.0
  Voermans et al\[[@B24]\]     2012       Prospective Multi-center       Netherlands                                     36                   \-                                      \-                   32/36                         \-                                       \-      \-     32/26   1-26   0.0
  Lee et al\[[@B26]\]          2017       Prospective Multi-center       Korea                                           19                   1/4                                     \-                   1/1                           10/12                                    1/2     \-     13/19   72     0.0
  Arezzo et al\[[@B28]\]       2012       Case series Prospective        Italy                                           14                   \-                                      \-                   \-                            12/14                                    \-      \-     12/14   16     0.0
  Schlag et al\[[@B29]\]       2013       Prospective                    Germany                                         6                    \-                                      \-                   6/6                           \-                                       \-      \-     6/6     4-12   0.0
  Gubler et al \[[@B31]\]      2012       Case series Prospective        Switzerland                                     14                   \-                                      \-                   12/14                         \-                                       \-      \-     12/14   4-48   NR
  Singhal et al\[[@B32]\]      2014       Case series Prospective        United States                                   10                   9/10                                    \-                   \-                            \-                                       \-      \-     9/10    7      0.0
  Schmidt et al\[[@B4]\]       2015       Prospective Multi-center RCT   International[1](#T5FN1){ref-type="table-fn"}   24                   \-                                      \-                   \-                            \-                                       18/24   \-     18/24   4      2 (8.3)
  Correia et al\[[@B36]\]      2014       Case series Prospective        Portugal                                        6                    4/5                                     \-                   1/1                           \-                                       \-      \-     5/6     NR     0.0
  Goenka et al\[[@B37]\]       2017       Prospective                    India                                           12                   2/3                                     6/6                  3/3                           \-                                       \-      \-     11/12   4-8    0.0
  Surace et al\[[@B38]\]       2011       Prospective                    Italy                                           19                   14/19                                   \-                   \-                            \-                                       \-      \-     14/19   32     1 (5.3)
  Kochhar et al\[[@B39]\]      2017       Case series Prospective        United States                                   12                   \-                                      \-                   \-                            8/12                                     \-      \-     8/12    60     1 (8.3)
  Manta et al\[[@B40]\]        2017       Prospective                    Italy                                           76                   \-                                      \-                   \-                            61/76                                    \-      \-     61/76   NR     0.0
  Parodi et al\[[@B41]\]       2010       Prospective                    Italy                                           10                   4/5                                     \-                   3/3                           1/2                                      \-      \-     8/10    NR     0.0
  Sulz et al\[[@B52]\]         2014       Case series Prospective        Switzerland                                     19                   6/11                                    1/1                  \-                            4/6                                      \-      1/1    12/19   NR     0.0
  Magdeburg et al\[[@B53]\]    2015       Prospective                    Germany                                         43                   \-                                      \-                   42/43                         \-                                       \-      \-     42/43   NR     3 (7.0)
  Keren et al\[[@B55]\]        2014       Case series Prospective        Israel                                          26                   \-                                      \-                   \-                            21/26                                    \-      \-     21/26   NR     0.0
  Hagel et al\[[@B57]\]        2012       Case series Prospective        Germany                                         17                   \-                                      \-                   11/17                         \-                                       \-      \-     11/17   4      NR
  Mangiafico et al\[[@B63]\]   2017       Case series Prospective        International[2](#T5FN2){ref-type="table-fn"}   7                    7/7                                     \-                   \-                            \-                                       \-      \-     7/7     2-8    0.0
  Schmdtt et al\[[@B4]\]       2018       Prospective RCT                International[3](#T5FN3){ref-type="table-fn"}   33                   \-                                      28/33                \-                            \-                                       \-      \-     28/33   4      0.0
  Prosst et al\[[@B66]\]       2015       Prospective                    Germany                                         20                   18/20                                   \-                   \-                            \-                                       \-      \-     18/20   24     0.0
  Mizrahi et al\[[@B67]\]      2016       Prospective                    United States                                   51                   6/17                                    3/4                  3/4                           12/24                                    \-      1/2    25/51   48     NR
  Chan et al \[[@B75]\]        2014       Case series Prospective        China                                           9                    \-                                      7/9                  \-                            \-                                       \-      \-     7/9     8      NR
  Keen et al\[[@B76]\]         2019       Prospective                    United Kingdom                                  59                   \-                                      55/59                \-                            \-                                       \-      \-     55/59   4      NR
  Tashima et al\[[@B85]\]      2017       Prospective                    Japan                                           50                   \-                                      \-                   \-                            \-                                       47/50   \-     47/50   2      4 (8)
  Kappelle et al\[[@B89]\]     2018       Prospective                    Netherlands                                     13                   \-                                      \-                   \-                            \-                                       11/13   \-     11/13   24     5 (38.4)
  Total                        617        70.3%                          89.3%                                           89.1%                75.0%                                   87.1%                66.7%                         81.7%                                    \-      3.4%                  
  71/101                       100/112    114/128                        129/172                                         88/101               2/3                                     504/617              \-                            16/467[4](#T5FN4){ref-type="table-fn"}                                 

Switzerland, Germany.

Italy, United Kingdom.

Germany, China, Switzerland.

Over the scope clip-related adverse events were only reported for 467 of 617 patients (*n* = 21 studies). NR: Not reported; ER: Endoscopic resection; RCT: Randomized control trial.

In conclusion, it is clear that the OTSC device represents a major advance in endoscopic practice and has enabled a "paradigm shift" in how we manage a variety of endoscopic challenges today. Our systematic review demonstrates that the OTSC system is a safe and effective endoscopic therapy to manage GI hemorrhage, perforation, anastomotic leaks, defects created by endoscopic resection, and for stent fixation; however, success in fistulae was limited. Further studies, including randomized controlled trials comparing OTSC with conventional and/or surgical therapies, are needed to determine which indication(s) are the most appropriate for its use and also to clarify the true AE rate, need for surgical salvage and any other technical aspects of OTSC use that may further clarify the role of OTSC in current and future endoscopic practice.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

The over-the-scope-clip (OTSC) device has become widely utilized in endoscopic practice. Limited data exist evaluating the overall clinical success and adverse event (AE) rates of OTSC across gastrointestinal (GI) indications.

Research motivation
-------------------

The key significance of this systematic review is to provide endoscopists with a real-world estimate of the efficacy and safety of OTSC in clinical practice.

Research objectives
-------------------

The aim of this study was to determine the rates of clinical success (CSR), technical success (TSR), AE and post-OTSC (salvage) surgery rates.

Research methods
----------------

A PubMed search was conducted for eligible articles describing the use of OTSC for any GI indication. Any article or case series reporting data for less than 5 total patients was excluded. Articles were included from January 1, 2007 to January 15, 2020. The following terms were used to perform the literature search: "over-the-scope-clip", "OTSC", "endoscopic fistula closure," "over-the-scope clip bleeding", "stent fixation", and "endoscopic perforation closure."

Research results
----------------

Eighty-five articles met inclusion criteria (*n* = 3025 patients*)*. The overall CSR (inclusive of all indications) and TSR for OTSC placement was 78.4% (*n* = 2371/3025) and 94.4% (*n* = 2856/3025), respectively.

Research conclusions
--------------------

OTSCs are a novel advancement in endoscopic practice. They are safe and effective for use in GI hemorrhage, anastomotic leak, perforation, defects created by endoscopic resection and stent fixation; however, there is room for improvement in use for fistula closure.

Research perspectives
---------------------

Future large randomized control trials comparing OTSC with conventional and/or surgical interventions are needed to develop clinical guidelines for the most appropriate endoscopic application(s).
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